• Share:

Publications 2012

Can't find the PDF you are looking for? Email Jessica Kohn for assistance.

 

Publications: 2012

 

Li L, Fukunaga-Kalabis M, Herlyn M. Isolation and cultivation of dermal stem cells that differentiate into functional melanocytes. Methods Mol Biol. 2012;806:15-29. Link to Article

Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nature Protocols. 2012;7:235-246. Link to Article

Herlyn M. New dream team for melanoma therapy. Pigm Cell Mel Res. 2012;25:279-280. Link to Article

Lee JT, Herlyn M. MEK’ing the most of p53 reactivation therapy in melanoma. J Invest Dermatol. 2012;132:263-265. Link to Article

Slipcevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala J Med Sci. 2012;117:237-243. Link to Article

Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfisterhammer K, Gschaider M, Lai CY, Hsu M-Y, Herlyn M, Stingl G, Wagner SN. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 2012;20:1056-1062. Link to Article

Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biol Open. 2012;1:516-526. Link to Article

Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigm Cell Mel Res. 2012;25:493-505. Link to Article

Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler JD, Marmorstein R. Identification of a novel family of BRAFV600E inhibitors. J Med Chem. 2012;55:5220-5230. Link to Article

Furney SJ, Turajlic S, Fenwick K, Lambros MB, Mackay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R. Genomic characterisation of acral melanoma cell lines. Pigment Cell Mel Res. 2012;25:488-492. Link to Article

Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nature Med. 2012;18:853-854. Link to Article

Herlyn M. Randy Lomax - the passionate melanoma advocate and champion of the Melanoma Research Foundation. Pigm Cell Mel Res. 2012;25:832-833. Link to Article

John JK, Paraiso KHT, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KSM. GSK3ß inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol. 2012;132:2818-2827. Link to Article

Naganuma S, Whelan KA, Natsuizaka S, Kinugasa H, Chang S, Subramanian H, Rhoades B, Ohashi S, Itoh H, Herlyn M, Diehl JA, Gimotty PA, Klein-Szanto AJ, Nakagawa H. Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma. Am J Cancer Res. 2012;2:459-475. Link to Article

Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? J Invest Dermatol. 2012;132:2133-2134. Link to Article

Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C. Development of a novel class of B-RAF (V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem. 2012;10:7402-7417. Link to Article

Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, Puré E. Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med Genomics. 2012;5:39. Link to Article

Chae YC, Caino MC, Lisanti S, Gosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90. Cancer Cell. 2012;22:331-344. Link to Article

Maurer M, Somasundaram R, Herlyn M, Wagner SN. Immunotargeting of tumor subpopulations in melanoma patients: a paradigm shift in therapy approaches. Oncoimmunology. 2012;1:1454-1456. Link to Article

Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Advances Pharmacol. 2012;65:335-359. Link to Article

Facombre N, Nakagawa H, Herlyn M, Basu D. Stem-like therapy and therapy resistance in squamous cell carcinoma. Advances in Pharmacol. 2012;65:359-365. Link to Article

Räsänen K, Herlyn M. Paracrine signaling between carcinoma cells and mesenchymal stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discov. 2012;2:775-779. Link to Article

Fukunaga-Kalabis M, Herlyn M. Cancer: complexion matters. Nature. 2012;491:342-343. Link to Article

Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live melanoma samples using a novel automated platform. PLos One. 2012;7:e52760. Link to Article